Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | STK3 | Q13188 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673498 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2ARAB9APIM1 | |
| SCHEMBL15453284 | 0.84 | GSK3B (0.39) | RAB9ALOXL2GSK3BMAPK1CYP1A2 | |
| SCHEMBL7686070 | 0.82 | MAPK1 (0.43) | RAB9APIM1PDGFRBALDH1A1MAPK1 | |
| SCHEMBL25610999 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL12068347 | 0.82 | GSK3B (0.49) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL8723967 | 0.82 | NOTUM (0.39) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL1917870 | 0.82 | ADORA3 (0.50) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL14895111 | 0.82 | LOXL2 (0.47) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL7064321 | 0.81 | IDH1 (0.39) | SMN1; SMN2MEN1KMT2ARAB9APDGFRB | |
| SCHEMBL6618330 | 0.79 | GSK3B (0.44) | SMN1; SMN2RAB9AADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642901-B1 | Novel erythromycin derivatives | PFIZER PROD INC (US) | 2007-10-31 | — | — | EP | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | claimed |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | WU YONG-JIN (US) | 2001-08-23 | — | — | US | claimed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | claimed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | claimed |
| EP-1044208-A1 | ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1999035157-A1 | NOVEL ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | claimed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | claimed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| WO-1998051696-A1 | ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | CYP7A1, HSD17B7, CYP51A1 | SMN1; SMN2 2559/4885MEN1 1734/4885KMT2A 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.